The FDA has approved Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia in adults.

Rapid RTX infusion protocols appear to be a safe option for patients with autoimmune rheumatic diseases, potentially reducing the time spent in infusion clinics.

Long-term denosumab therapy led to improved BMD among patients with RDs, regardless of GC usage or renal function.

The Food and Drug Administration has granted Fast Track designation to CELZ-201-DDT for the treatment of degenerative disc disease.

High continuous metabolic syndrome severity score trajectory pattern was linked to increased risk for CKD in adjusted analyses.

GLP-1 RA injectable use prevalence among adults with diabetes was 26.5% in 2024, but rates were higher in some age and racial groups.

Complete or partial renal response and lupus low disease activity state were associated with lupus nephritis relapse risk reduction.